open label, single arm Phase 1/2 study for the treatment of sever localized scleroderma .
Phase of Trial: Phase I/II
Latest Information Update: 18 Apr 2018
At a glance
- Drugs FCX-013 (Primary)
- Indications Scleroderma
- Focus Adverse reactions; Therapeutic Use
- 18 Apr 2018 According to Fibrocell media release, company expects to begin enrolment in this trial in the third quarter of 2018.
- 12 Mar 2018 New trial record
- 06 Mar 2018 According to Fibrocell media release, U.S. Food and Drug Administration (FDA) has granted allowance of its Investigational New Drug (IND) Application for FCX-013 to begin clinical trials for the treatment of moderate to severe localized scleroderma.